-transparent.png){kind=logo}
Twelve patients (2 with only bone metastases, 3 with only soft tissues metastases and 7 with bone and soft tissues metastases) were treated with 131-I-MIBG (specific activity: 20 mCi/mg), 100 to 200 mCi every 3-6 months. A dosimetric study was carried out before each administration. The follow-up ranged from 6 to 24 months and the number of doses ranged from 1 to 8, with 1.85-9 GBq per administration and a cumulative activity of 1.85-62. 2 GBq according to patients. The cumulative absorbed activity ranged from 850 to 9700 cGy. The following side effects were observed: a bone marrow hypoplasia (1 patient) and a transient increase in catecholamines (3 patients). The treatment was successful in 7 patients (3 with soft tissue metastases, 3 with bone and soft tissue metastases and one with bone metastases). This success consisted in clinical improvement and a decrease greater than 50% of hormonal values in the 7 patients and a decrease greater than 50% of tumoral masses in only 3 patients. No complete remission was obtained at this stage of the study. The disease recurred in 1 patient after a year of partial remission. There was no clear-cut relation between the number of doses and the results. This study shows that 131-I-MIBG can give encouraging though limited results.
B Charbonnel, and
J F Chatal, and
A J Brendel, and
B Lanehche, and
J Lumbroso, and
X Marchandise, and
R Mornex, and
M Schlumberger, and
J L Wemeau
August 1984,
Nihon rinsho. Japanese journal of clinical medicine,
B Charbonnel, and
J F Chatal, and
A J Brendel, and
B Lanehche, and
J Lumbroso, and
X Marchandise, and
R Mornex, and
M Schlumberger, and
J L Wemeau
August 1986,
Kaku igaku. The Japanese journal of nuclear medicine,
B Charbonnel, and
J F Chatal, and
A J Brendel, and
B Lanehche, and
J Lumbroso, and
X Marchandise, and
R Mornex, and
M Schlumberger, and
J L Wemeau
January 1991,
Journal of nuclear biology and medicine (Turin, Italy : 1991),
B Charbonnel, and
J F Chatal, and
A J Brendel, and
B Lanehche, and
J Lumbroso, and
X Marchandise, and
R Mornex, and
M Schlumberger, and
J L Wemeau
March 1990,
Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica,
B Charbonnel, and
J F Chatal, and
A J Brendel, and
B Lanehche, and
J Lumbroso, and
X Marchandise, and
R Mornex, and
M Schlumberger, and
J L Wemeau
May 2016,
Seminars in nuclear medicine,
B Charbonnel, and
J F Chatal, and
A J Brendel, and
B Lanehche, and
J Lumbroso, and
X Marchandise, and
R Mornex, and
M Schlumberger, and
J L Wemeau
December 2003,
Surgery,
B Charbonnel, and
J F Chatal, and
A J Brendel, and
B Lanehche, and
J Lumbroso, and
X Marchandise, and
R Mornex, and
M Schlumberger, and
J L Wemeau
August 1999,
American journal of clinical oncology,
B Charbonnel, and
J F Chatal, and
A J Brendel, and
B Lanehche, and
J Lumbroso, and
X Marchandise, and
R Mornex, and
M Schlumberger, and
J L Wemeau
February 1984,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
B Charbonnel, and
J F Chatal, and
A J Brendel, and
B Lanehche, and
J Lumbroso, and
X Marchandise, and
R Mornex, and
M Schlumberger, and
J L Wemeau
July 1998,
Clinical nuclear medicine,
B Charbonnel, and
J F Chatal, and
A J Brendel, and
B Lanehche, and
J Lumbroso, and
X Marchandise, and
R Mornex, and
M Schlumberger, and
J L Wemeau
October 1991,
Southern medical journal,
